Avadel Pharmaceuticals (AVDL): FDA Reviews of FT-218 Continues to Make Progress - Needham & Company
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $16.00 price target on Avadel Pharmaceuticals (NASDAQ: AVDL) saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
